帕金森氏症市场:KOL的洞察

本报告提供全球帕金森氏症市场相关调查，提供市场概要，以及已通过核准治疗方法，开发平台趋势，未来预测等资讯。

目录

摘要整理

现在及未来的治疗流程

调查目的

对帕金森氏症的目前治疗方法

• 重要的洞察概要

已通过核准治疗方法

• 多巴胺促效剂
• 固定用量组合药物
• MAO-B抑制剂
• COMT抑制剂
• 其他

开发平台(管线)治疗方法

• 多巴胺促效剂
• 固定用量联合治疗
• 其他的作用机制
• 初期阶段的药物候补
• 其他的作用机制/开发平台(管线)候补
• 数位萤幕/穿戴式

未来的治疗范例

• 重要的洞察概要

附录

Where do KOLs see an opportunity for GSK's transdermal dopamine agonist ropinirole? How do KOLs assess the competing benefits of AbbVie's Duopa/Duodopa and levodopa/carbidopa fixed dose combinations? What challenges and benefits do experts see for AbbVie's ABBV-951 pipeline subcutaneous levodopa + carbidopa combination? Why do KOLs say disease modification by inhibiting alpha-synuclein remains a complex proposition? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (12)

Current and future treatment algorithm

Research objectives (3)

Current practice for treating Parkinson's disease (3)

• Key insights summary (3)
  • First-line treatment for PD is usually levodopa, a dopamine agonist or a MAO-B inhibitor, depending on symptom severity, age, health, concomitant diseases and patient formulation preference (1)

Approved therapies (69)

• Dopamine agonists (21)
  • Key insights summary (21)
• Fixed-dose combination agents (17)
  • Key insights summary (17)
• MAO-B inhibitors (12)
  • Key insights summary (12)
• COMT inhibitors (11)
  • Key insights summary (11)
• Other agents (8)
  • Key insights summary (8)

Pipeline therapies (133)

• Dopamine agonists (21)
  • LY03003 (rotigotine intramuscular injection; Luye Pharma Group) (8)
  • Aplindore (DAB 452; Seelos Therapeutics) (6)
  • Tavapadon (Cerevel Therapeutics) (7)
• Fixed-dose combination therapies (26)
  • Levodopa + carbidopa subcutaneous infusions (2)
  • ABBV-951 (Produodopa; foslevodopa + foscarbidopa subcutaneous infusion; AbbVie) (8)
  • ND0612 (levodopa + carbidopa subcutaneous infusion; NeuroDerm/Mitsubishi Tanabe Pharma) (4)
  • IPX203 (levodopa + carbidopa extended-release; Amneal Pharmaceuticals) (5)
  • P2B001 (pramipexole + rasagiline; Pharma Two B) (7)
• Other modes of action (33)
  • Levodopa Cyclops dry powder inhaler (PureIMS) (8)
  • DNL151 (Denali Therapeutics/Biogen) (6)
  • Nabilone FDT (AOP Orphan Pharmaceuticals) (6)
  • Mesdopetam (Integrative Research Laboratories) (7)
  • Buntanetap (R-phenserine; Posiphen; Annovis Bio) (6)
• Early-phase drug candidates (38)
  • Alpha-synuclein inhibitors (2)
  • UCB0599 (UCB) (1)
  • PRX002 (prasinezumab; Roche) (1)
  • ENT-01 (kenterin; Enterin) (1)
  • ION464 (Ionis Pharma/Biogen) (6)
  • Repurposed drugs (2)
  • Tasigna (nilotinib; Novartis) (8)
  • Cell transplantation therapies (2)
  • Cell therapies (GRF6021 [Alkahest/Grifols], NeurotrophinCell [Living Cell Technologies]) (7)
  • Viral gene delivery approaches (8)
• Other mechanisms of action/pipeline candidates (8)
  • Key insights summary (8)
• Digital monitors/wearables (7)
  • Key insights summary (7)

Future treatment paradigm (7)

• Key insights summary (7)
  • With disease modification a slim prospect in the next five years, the focus may remain on better management of fluctuations, dyskinesia and other pressing needs like frozen gait or dementia (5)

Appendix (4)

• KOL details (4)
  • KOLs from North America (1)
  • KOLs from Europe (2)